Halberd Corporation (HALB) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Halberd Corporation (HALB) trades at $0.0006 with AI Score 39/100 (Grade D). Halberd Corporation is a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for HALB: HALB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HALB against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HALB: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Halberd Corporation (HALB) Healthcare & Pipeline Overview
Halberd Corporation (HALB) is a pioneering biotechnology firm dedicated to developing therapies for neurodegenerative diseases, including PTSD, CTE, and Alzheimer's, with a focus on innovative solutions in a rapidly evolving healthcare landscape.
What Is the Investment Thesis for HALB?
Halberd Corporation presents a unique investment thesis centered around its innovative approach to treating neurodegenerative diseases. Halberd's focus on serious conditions such as PTSD, CTE, and Alzheimer's disease aligns with increasing awareness and funding for mental health and neurodegenerative research. However, the company faces significant challenges, including the need for substantial funding to advance its research and development efforts, as well as the regulatory hurdles associated with bringing new therapies to market. The micro-cap nature of Halberd, with a market cap of approximately $619,050, implies high volatility and liquidity risks, necessitating careful monitoring of its operational progress and funding capabilities. Achieving successful clinical outcomes and securing partnerships could serve as key growth catalysts, potentially enhancing the company's market position and investor interest.
Based on FMP financials and quantitative analysis
HALB Key Highlights
Market cap of approximately $619,050 reflects a micro-cap valuation, indicating high volatility.
- Focus on neurodegenerative diseases positions Halberd in a growing healthcare segment with increasing demand.
- Small workforce of three employees allows for agile decision-making but raises concerns about operational capacity.
- Beta of 0.15 suggests lower volatility compared to the broader market, although liquidity risks remain.
- No dividend yield indicates a focus on reinvestment in research and development.
Who Are HALB's Competitors?
HALB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $442.36 | +4.02% | $239B | 86 |
| BIIB Biogen Inc. | $217.35 | -1.90% | $32.1B | 64 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HALB's Key Strengths?
Innovative focus on neurodegenerative diseases.
- Small team allows for agile decision-making.
- Established in a growing healthcare sector.
What Are HALB's Weaknesses?
Limited workforce may hinder operational capacity.
- Micro-cap valuation presents liquidity risks.
- Dependence on securing funding for research.
What Could Drive HALB Stock Higher?
Potential partnerships with research institutions to enhance R&D capabilities.
- Development of therapies for PTSD and CTE, addressing significant market needs.
- Exploration of funding opportunities to support clinical trials and research.
What Are the Key Risks for HALB?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- High regulatory hurdles associated with bringing new therapies to market.
- Market volatility impacting funding opportunities and investor sentiment.
- Intense competition from larger pharmaceutical companies in the biotechnology sector.
What Are the Growth Opportunities for HALB?
- Expansion into PTSD therapies: Halberd Corporation is exploring the development of therapies specifically targeting PTSD, a condition affecting millions globally. The market for PTSD treatments is projected to grow significantly, with estimates suggesting a value of $5 billion by 2027. Halberd's innovative approach could provide a competitive edge in this expanding market.
- Innovative solutions for CTE: Chronic traumatic encephalopathy (CTE) is gaining attention due to its association with contact sports and military service. Halberd's focus on CTE therapies aligns with a growing demand for effective treatments, potentially positioning the company as a leader in this niche market, which is expected to see increased funding and research activity over the next five years.
- Development of cancer therapies: The oncology market is one of the fastest-growing segments in healthcare, with an estimated value of $200 billion by 2025. Halberd's commitment to developing therapies for various forms of cancer could tap into this lucrative market, provided the company can navigate the complex regulatory landscape and secure necessary funding.
- Partnerships with research institutions: Collaborating with universities and research institutions could enhance Halberd's R&D capabilities and accelerate the development of its therapies. Such partnerships could also provide access to additional funding sources and expertise, potentially leading to faster clinical trials and product development.
- Geographic expansion: As Halberd continues to develop its therapies, expanding its reach into international markets could provide significant growth opportunities.
What Are HALB's Competitive Advantages?
- Focus on innovative therapies for high-need medical conditions.
- Small, agile team allows for quick decision-making and adaptation.
- Potential for unique intellectual property in therapeutic areas.
What Does HALB Do?
Founded in 2009, Halberd Corporation is a biotechnology firm headquartered in Jackson Center, Pennsylvania. The company is dedicated to developing groundbreaking therapies aimed at treating a variety of neurodegenerative conditions, including post-traumatic stress disorder (PTSD), chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, and various forms of cancer. With a small team of three employees, Halberd Corporation has positioned itself within the healthcare sector as an innovator focused on serious illnesses that significantly impact quality of life. The company’s research and development efforts are geared towards creating effective treatments for disorders affecting the blood and cerebrospinal fluid, showcasing its commitment to addressing unmet medical needs. Over the years, Halberd has leveraged its expertise in biotechnology to explore therapeutic avenues that could lead to significant advancements in patient care. Despite its small size and limited market capitalization, Halberd Corporation's focus on neurodegenerative diseases places it in a crucial segment of the healthcare industry, which is increasingly gaining attention due to the rising prevalence of these conditions. As the global population ages, the demand for effective treatments for neurodegenerative diseases is expected to grow, potentially enhancing Halberd's relevance and impact in the market.
What Products and Services Does HALB Offer?
- Develop therapies for neurodegenerative diseases.
- Focus on conditions such as PTSD, CTE, Alzheimer's, and Parkinson's.
- Conduct research and development in biotechnology.
- Explore innovative solutions for serious health conditions.
- Aim to address unmet medical needs in the healthcare sector.
- Operate from Jackson Center, Pennsylvania, with a small team.
How Does HALB Make Money?
- Generate revenue through the development and commercialization of therapies.
- Focus on securing funding for research and clinical trials.
- Potential partnerships with pharmaceutical companies for product development.
- Explore government and private grants for research initiatives.
What Industry Does HALB Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in medical technology and increasing investment in research and development. As the global population ages, the prevalence of neurodegenerative diseases is expected to rise, creating a significant market opportunity for companies like Halberd Corporation. Halberd's focus on innovative therapies positions it within a competitive landscape that includes both established pharmaceutical companies and emerging biotech firms, all vying for a share of this lucrative market.
Who Are HALB's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Healthcare providers seeking innovative treatment options.
- Research institutions collaborating on therapeutic development.
- Potential pharmaceutical partners for commercialization.
How Halberd Corporation Is Valued
Relative to its peer group, HALB's quantitative score of 39/100 is below the peer average of 79/100.
Company Profile
Halberd Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jackson Center, US. The company is led by CEO William A. Hartman. HALB has traded publicly since 2012.
Key Financial Metrics
Return on equity for Halberd Corporation stands at 5.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -6.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Halberd Corporation's Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
HALB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Halberd's insider buying could signal strong confidence in the company's future prospects, suggesting they believe the stock is undervalued. The community's growing excitement around Halberd's innovative technology might be a precursor to increased market attention and demand. Positive community sentiment often translates to increased trading volume and potential upward price movement. Halberd's recent strategic partnerships could open new revenue streams and expand their market reach, boosting investor confidence.
Bear Case
- Lack of detailed information regarding Halberd's technology makes it difficult to assess its true potential and market viability. Negative community discussions surrounding management decisions could erode investor trust and lead to selling pressure. The company's limited track record in a highly competitive industry raises concerns about its ability to execute its business plan effectively. Skepticism persists within the community due to past unfulfilled promises, potentially hindering future growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HALB Latest News
No recent news available for HALB.
HALB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HALB.
Price Targets
Wall Street price target analysis for HALB.
HALB MoonshotScore
What does this score mean?
The MoonshotScore rates HALB 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: William A. Hartman
CEO
William A. Hartman has been at the helm of Halberd Corporation since its inception in 2009. With a background in biotechnology and a passion for addressing unmet medical needs, Hartman has guided the company through its early development stages. His leadership is characterized by a commitment to innovation and a focus on therapeutic solutions for serious health conditions.
Track Record: Under Hartman's leadership, Halberd has established its focus on neurodegenerative diseases and has begun to carve out a niche in the biotechnology sector. His strategic decisions have positioned the company to explore innovative therapeutic avenues, although challenges remain in securing funding and achieving clinical milestones.
HALB OTC Market Information
The OTC Other tier is a classification for companies that do not meet the requirements for higher tiers such as OTCQX or OTCQB. This tier typically includes smaller, less liquid companies, which can lead to higher volatility and less stringent reporting requirements compared to major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited operational capacity due to a small workforce.
- High volatility associated with micro-cap stocks.
- Dependence on external funding for research and development.
- Verify the company's financial health and funding sources.
- Assess the progress of clinical trials and regulatory approvals.
- Investigate partnerships and collaborations in the biotechnology space.
- Review management's track record and industry experience.
- Monitor market trends in neurodegenerative disease therapies.
- Established in 2009, indicating a history in the biotechnology sector.
- Focus on serious health conditions, aligning with significant market needs.
- Engagement in research and development activities.
What Investors Ask About Halberd Corporation (HALB) — Healthcare
What does the AI Score mean for HALB?
HALB holds an AI Score of 39/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Halberd Corporation is a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases. Established in 2009, the company operates from Jackson Center, Pennsylvania …
What does Halberd Corporation do?
Halberd Corporation is a biotechnology firm focused on developing innovative therapies for neurodegenerative diseases, including PTSD, CTE, Alzheimer's, and various cancers. The company conducts research and development to address serious health conditions, aiming to create effective treatments that meet unmet medical needs.
What are the key growth opportunities for HALB in healthcare?
Halberd Corporation has several key growth opportunities, including the expansion into PTSD therapies, which is a growing market projected to reach $5 billion by 2027.
What are the main risks for HALB?
Halberd Corporation faces several risks, including high regulatory hurdles in the biotechnology sector, which can impede the development and approval of new therapies. Additionally, the company operates in a highly competitive landscape with larger pharmaceutical firms, which may affect its market position and funding opportunities. The micro-cap nature of HALB also presents liquidity risks, making it susceptible to market volatility.
What are the key factors to evaluate for HALB?
Halberd Corporation (HALB) holds an AI score of 39/100 (low). Halberd Corporation presents a unique investment thesis centered around its innovative approach to treating neurodegenerative diseases. Not financial advice.
How frequently does HALB data refresh on this page?
HALB's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HALB's recent stock price performance?
Halberd Corporation (HALB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative focus on neurodegenerative diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HALB overvalued or undervalued right now?
Halberd Corporation (HALB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HALB before investing?
Before investing in Halberd Corporation (HALB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial reporting and operational transparency.